The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Lakshmikumaran & Sridharan

Work +91 11 4129 9811
Fax +91 11 4129 9899
Chennai, Geneva, Mumbai, New Delhi


Antitrust and competition
Antitrust and competition - ranked: tier 1

LakshmiKumaran & Sridharan

At LakshmiKumaran & Sridharan, the ‘detailed’, ‘focused’ and ‘very knowledgeable and experienced team’ includes T Sundar Ramanathan, who is ‘hard working’ and ‘experienced’, and ‘calm and patient listener’ Abir Roy; the duo are acting for NOK in the CCI’s investigation into the global auto cartel, including challenging the CCI’s jurisdiction in this matter before the Delhi High Court. Principal associate Prashanth Shivadass is also recommended. Former practice head S Seetharaman left to launch Seetharaman & Associates in 2017.

Leading individuals

Abir Roy - LakshmiKumaran & Sridharan

[back to top]

Intellectual property
Intellectual property - ranked: tier 4

LakshmiKumaran & Sridharan

Lakshmikumaran & Sridharan specialises in contentious patent and trade secret disputes, international patent applications, and patent prosecution. Clients have included BASF, Merck & Co and Microsoft, and R Parthasarathy heads the practice.

[back to top]

Tax - ranked: tier 1

LakshmiKumaran & Sridharan

LakshmiKumaran & Sridharan is strong on tax litigation and advisory matters, and counts Sun Pharmaceutical, ICICI Bank and Mondelez among its clients. V Lakshmi Kumaran represented MakeMyTrip before the High Court regarding the arrest of one of its officials in connection with payment of service tax, and Narasimhan B L advised Nestlé on the classification and payable duty of its milk drink products. L Badri Narayanan and senior associate Charanya Lakshmikumaran are also noted.

Leading individuals

V Lakshmikumaran - LakshmiKumaran & Sridharan

Next generation lawyers

Charanya Lakshmikumaran - LakshmiKumaran & Sridharan

[back to top]

WTO/international trade
WTO/international trade - ranked: tier 2

LakshmiKumaran & Sridharan

The ‘competent’ practice at LakshmiKumaran & Sridharan handles domestic taxation matters and has its strengths in anti-dumping and countervailing duty investigations. Principal associate Edouard Descotis has ‘very good knowledge’ in this space and is ‘hardworking, methodical, and sincere’. Former key contact S Seetharaman left to launch Seetharaman & Associates in 2017.

[back to top]

Further information on Lakshmikumaran & Sridharan

Please choose from this list to view details of what we say about Lakshmikumaran & Sridharan in other jurisdictions.


Offices in New Delhi, Mumbai, and Chennai

Legal Developments in India

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Sulphur Cap Ahead - Regulatory

    Sulphur Cap Ahead - Regulatory
  • GTDT Shipping - India

    Mr Shardul Thacker heads the shipping, oil and gas and banking practice group at Mulla & Mulla & Craigie Blunt & Caroe. Lloyd’s List ranked him third in their top 10 lawyers stating: “Highly regarded for his work in the liquefied natural gas sector, particularly for interesting and highly geared finance deals in relation to infrastructure projects, energy, ports and ships.” india_-_gtdt_shipping_
  • Chambers Guides - Insurance 2018 - India

    India is a common-law jurisdiction. In general, Indian laws borrow heavily from, and are based on, English law. However, insurance law in India has certain unique features that deviate from English insurance law. The primary legislation of insurance law in India is the Insurance Act, 1938 (the “Insurance Act”) and the Insurance Rules, 1939 (the “Insurance Rules”).
  • Transport Finance Review - India

    The transportation industry – aviation, shipping and rail – has been predominantly owned by government entities since India’s independence in 1947. Air India and Indian Airlines, both government-owned, rules the skies; the Shipping Corporation of India (SCI), established in 1961 and owned by the government, owns and operates around one-third of the Indian tonnage. All railway property is government owned.
  • International Arbitration Review - India

    The Arbitration and Conciliation Act, 1996 (Act) provides the framework for arbitration and conciliation in India. Drafted on the basis of the UNCITRAL Model Law, it is divided into four parts. Each part governs a different aspect of the arbitration and conciliation process: a Part 1 governs commercial arbitration; b Part 2 governs the enforcement of certain foreign awards; c Part 3 governs conciliation; and d Part 4 contains supplementary provisions (regarding the power of the court to make rulings, etc.). The Act 2 was recently amended in 2016 with an aim to make it more robust by plugging the lacunae that existed in the original legislation.
  • ICLG Shipping law 2018 - India

  • India - Chambers Guides - Shipping 2018

    The ‘Law & Practice’ sections provide easily accessible information on navigating the legal system when conducting business in the jurisdiction. Leading lawyers explain local law and practice at key transactional stages and for crucial aspects of doing business.

  • Post Marketing Surveillance of Drugs

    Post marketing surveillance is performed after market approval/clinical trials of drugs in India. The regulatory framework for conducting clinical trials of drugs is provided under the Drugs and Cosmetics Act, 1940 (“ Act ”) and the Drugs and Cosmetics Rules, 1945 (“ Rules ”). Further, Part X-A and Schedule Y of the Rules specifically deal with the statutory provisions applicable for clinical trial of drugs in India. Schedule Y divides Clinical trial of drugs into 4 Phases, namely, Human Pharmacology (Phase-I), Therapeutic exploratory trials (Phase-II), Therapeutic confirmatory trials (Phase III) and Post Marketing Trials (Phase-IV).
  • Protection of Biotechnology under Indian Laws

    According to the eighth annual survey conducted by the Association of Biotechnology-Led Enterprises (ABLE) and Bio Spectrum, the Indian biotech industry grew threefold in just five years to report revenues of US$ 3 billion in 2009-10, a rise of 17 per cent over the previous year. Maintaining the momentum of the previous years, the Indian biotech industry grew 16.28 per cent in FY2014; the total industry size was US$ 5 billion at the end of the financial year and it reached US$ 7 billion in FY2015. Fast-paced growth is likely to continue; the industry is expected to increase in size to USD11.6 billion by 2017, driven by a range   of factors such as growing demand, intensive R & D activities and strong government initiatives ( )